CN113181365A - Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof - Google Patents
Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof Download PDFInfo
- Publication number
- CN113181365A CN113181365A CN202110272571.0A CN202110272571A CN113181365A CN 113181365 A CN113181365 A CN 113181365A CN 202110272571 A CN202110272571 A CN 202110272571A CN 113181365 A CN113181365 A CN 113181365A
- Authority
- CN
- China
- Prior art keywords
- uric acid
- lactobacillus
- composition
- tophus
- cfu
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 114
- LEHOTFFKMJEONL-UHFFFAOYSA-N Uric Acid Chemical compound N1C(=O)NC(=O)C2=C1NC(=O)N2 LEHOTFFKMJEONL-UHFFFAOYSA-N 0.000 title claims abstract description 99
- TVWHNULVHGKJHS-UHFFFAOYSA-N Uric acid Natural products N1C(=O)NC(=O)C2NC(=O)NC21 TVWHNULVHGKJHS-UHFFFAOYSA-N 0.000 title claims abstract description 81
- 229940116269 uric acid Drugs 0.000 title claims abstract description 81
- 239000013078 crystal Substances 0.000 title claims abstract description 43
- 230000001603 reducing effect Effects 0.000 title claims abstract description 16
- 201000005569 Gout Diseases 0.000 claims abstract description 37
- 239000006041 probiotic Substances 0.000 claims abstract description 23
- 235000018291 probiotics Nutrition 0.000 claims abstract description 23
- 230000000529 probiotic effect Effects 0.000 claims abstract description 22
- 241000186604 Lactobacillus reuteri Species 0.000 claims abstract description 21
- 229940001882 lactobacillus reuteri Drugs 0.000 claims abstract description 21
- 235000013406 prebiotics Nutrition 0.000 claims abstract description 16
- 244000199866 Lactobacillus casei Species 0.000 claims abstract description 13
- 235000013958 Lactobacillus casei Nutrition 0.000 claims abstract description 13
- 229940017800 lactobacillus casei Drugs 0.000 claims abstract description 13
- 240000006024 Lactobacillus plantarum Species 0.000 claims abstract description 12
- 235000013965 Lactobacillus plantarum Nutrition 0.000 claims abstract description 12
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims abstract description 12
- 229940072205 lactobacillus plantarum Drugs 0.000 claims abstract description 12
- 241000894006 Bacteria Species 0.000 claims abstract description 7
- 241000193749 Bacillus coagulans Species 0.000 claims abstract description 6
- 241000186840 Lactobacillus fermentum Species 0.000 claims abstract description 6
- 229940054340 bacillus coagulans Drugs 0.000 claims abstract description 6
- 229940012969 lactobacillus fermentum Drugs 0.000 claims abstract description 6
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 claims description 48
- 239000003814 drug Substances 0.000 claims description 23
- 238000004321 preservation Methods 0.000 claims description 19
- 229940079593 drug Drugs 0.000 claims description 18
- 201000001431 Hyperuricemia Diseases 0.000 claims description 8
- 235000013305 food Nutrition 0.000 claims description 6
- 229960002529 benzbromarone Drugs 0.000 claims description 5
- WHQCHUCQKNIQEC-UHFFFAOYSA-N benzbromarone Chemical compound CCC=1OC2=CC=CC=C2C=1C(=O)C1=CC(Br)=C(O)C(Br)=C1 WHQCHUCQKNIQEC-UHFFFAOYSA-N 0.000 claims description 5
- 238000004090 dissolution Methods 0.000 claims description 5
- 229960005101 febuxostat Drugs 0.000 claims description 5
- BQSJTQLCZDPROO-UHFFFAOYSA-N febuxostat Chemical compound C1=C(C#N)C(OCC(C)C)=CC=C1C1=NC(C)=C(C(O)=O)S1 BQSJTQLCZDPROO-UHFFFAOYSA-N 0.000 claims description 5
- 238000011282 treatment Methods 0.000 claims description 4
- 229920001202 Inulin Polymers 0.000 claims description 3
- UQZIYBXSHAGNOE-USOSMYMVSA-N Stachyose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@H](CO[C@@H]2[C@@H](O)[C@@H](O)[C@@H](O)[C@H](CO)O2)O1 UQZIYBXSHAGNOE-USOSMYMVSA-N 0.000 claims description 3
- 229960003459 allopurinol Drugs 0.000 claims description 3
- OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 claims description 3
- HEBKCHPVOIAQTA-NGQZWQHPSA-N d-xylitol Chemical compound OC[C@H](O)C(O)[C@H](O)CO HEBKCHPVOIAQTA-NGQZWQHPSA-N 0.000 claims description 3
- 230000036541 health Effects 0.000 claims description 3
- JYJIGFIDKWBXDU-MNNPPOADSA-N inulin Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)OC[C@]1(OC[C@]2(OC[C@]3(OC[C@]4(OC[C@]5(OC[C@]6(OC[C@]7(OC[C@]8(OC[C@]9(OC[C@]%10(OC[C@]%11(OC[C@]%12(OC[C@]%13(OC[C@]%14(OC[C@]%15(OC[C@]%16(OC[C@]%17(OC[C@]%18(OC[C@]%19(OC[C@]%20(OC[C@]%21(OC[C@]%22(OC[C@]%23(OC[C@]%24(OC[C@]%25(OC[C@]%26(OC[C@]%27(OC[C@]%28(OC[C@]%29(OC[C@]%30(OC[C@]%31(OC[C@]%32(OC[C@]%33(OC[C@]%34(OC[C@]%35(OC[C@]%36(O[C@@H]%37[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O%37)O)[C@H]([C@H](O)[C@@H](CO)O%36)O)[C@H]([C@H](O)[C@@H](CO)O%35)O)[C@H]([C@H](O)[C@@H](CO)O%34)O)[C@H]([C@H](O)[C@@H](CO)O%33)O)[C@H]([C@H](O)[C@@H](CO)O%32)O)[C@H]([C@H](O)[C@@H](CO)O%31)O)[C@H]([C@H](O)[C@@H](CO)O%30)O)[C@H]([C@H](O)[C@@H](CO)O%29)O)[C@H]([C@H](O)[C@@H](CO)O%28)O)[C@H]([C@H](O)[C@@H](CO)O%27)O)[C@H]([C@H](O)[C@@H](CO)O%26)O)[C@H]([C@H](O)[C@@H](CO)O%25)O)[C@H]([C@H](O)[C@@H](CO)O%24)O)[C@H]([C@H](O)[C@@H](CO)O%23)O)[C@H]([C@H](O)[C@@H](CO)O%22)O)[C@H]([C@H](O)[C@@H](CO)O%21)O)[C@H]([C@H](O)[C@@H](CO)O%20)O)[C@H]([C@H](O)[C@@H](CO)O%19)O)[C@H]([C@H](O)[C@@H](CO)O%18)O)[C@H]([C@H](O)[C@@H](CO)O%17)O)[C@H]([C@H](O)[C@@H](CO)O%16)O)[C@H]([C@H](O)[C@@H](CO)O%15)O)[C@H]([C@H](O)[C@@H](CO)O%14)O)[C@H]([C@H](O)[C@@H](CO)O%13)O)[C@H]([C@H](O)[C@@H](CO)O%12)O)[C@H]([C@H](O)[C@@H](CO)O%11)O)[C@H]([C@H](O)[C@@H](CO)O%10)O)[C@H]([C@H](O)[C@@H](CO)O9)O)[C@H]([C@H](O)[C@@H](CO)O8)O)[C@H]([C@H](O)[C@@H](CO)O7)O)[C@H]([C@H](O)[C@@H](CO)O6)O)[C@H]([C@H](O)[C@@H](CO)O5)O)[C@H]([C@H](O)[C@@H](CO)O4)O)[C@H]([C@H](O)[C@@H](CO)O3)O)[C@H]([C@H](O)[C@@H](CO)O2)O)[C@@H](O)[C@H](O)[C@@H](CO)O1 JYJIGFIDKWBXDU-MNNPPOADSA-N 0.000 claims description 3
- 229940029339 inulin Drugs 0.000 claims description 3
- 238000002360 preparation method Methods 0.000 claims description 3
- 229960003081 probenecid Drugs 0.000 claims description 3
- DBABZHXKTCFAPX-UHFFFAOYSA-N probenecid Chemical compound CCCN(CCC)S(=O)(=O)C1=CC=C(C(O)=O)C=C1 DBABZHXKTCFAPX-UHFFFAOYSA-N 0.000 claims description 3
- UQZIYBXSHAGNOE-XNSRJBNMSA-N stachyose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO[C@@H]3[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O3)O)O2)O)O1 UQZIYBXSHAGNOE-XNSRJBNMSA-N 0.000 claims description 3
- MUPFEKGTMRGPLJ-RMMQSMQOSA-N Raffinose Natural products O(C[C@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](O[C@@]2(CO)[C@H](O)[C@@H](O)[C@@H](CO)O2)O1)[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 MUPFEKGTMRGPLJ-RMMQSMQOSA-N 0.000 claims description 2
- MUPFEKGTMRGPLJ-UHFFFAOYSA-N UNPD196149 Natural products OC1C(O)C(CO)OC1(CO)OC1C(O)C(O)C(O)C(COC2C(C(O)C(O)C(CO)O2)O)O1 MUPFEKGTMRGPLJ-UHFFFAOYSA-N 0.000 claims description 2
- FNAQSUUGMSOBHW-UHFFFAOYSA-H calcium citrate Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O FNAQSUUGMSOBHW-UHFFFAOYSA-H 0.000 claims description 2
- 239000001354 calcium citrate Substances 0.000 claims description 2
- 229960004256 calcium citrate Drugs 0.000 claims description 2
- 229960004106 citric acid Drugs 0.000 claims description 2
- 235000015165 citric acid Nutrition 0.000 claims description 2
- -1 citric acid ester Chemical class 0.000 claims description 2
- 238000007599 discharging Methods 0.000 claims description 2
- FTSSQIKWUOOEGC-RULYVFMPSA-N fructooligosaccharide Chemical compound OC[C@H]1O[C@@](CO)(OC[C@@]2(OC[C@@]3(OC[C@@]4(OC[C@@]5(OC[C@@]6(OC[C@@]7(OC[C@@]8(OC[C@@]9(OC[C@@]%10(OC[C@@]%11(O[C@H]%12O[C@H](CO)[C@@H](O)[C@H](O)[C@H]%12O)O[C@H](CO)[C@@H](O)[C@@H]%11O)O[C@H](CO)[C@@H](O)[C@@H]%10O)O[C@H](CO)[C@@H](O)[C@@H]9O)O[C@H](CO)[C@@H](O)[C@@H]8O)O[C@H](CO)[C@@H](O)[C@@H]7O)O[C@H](CO)[C@@H](O)[C@@H]6O)O[C@H](CO)[C@@H](O)[C@@H]5O)O[C@H](CO)[C@@H](O)[C@@H]4O)O[C@H](CO)[C@@H](O)[C@@H]3O)O[C@H](CO)[C@@H](O)[C@@H]2O)[C@@H](O)[C@@H]1O FTSSQIKWUOOEGC-RULYVFMPSA-N 0.000 claims description 2
- 229940107187 fructooligosaccharide Drugs 0.000 claims description 2
- 235000021255 galacto-oligosaccharides Nutrition 0.000 claims description 2
- 150000003271 galactooligosaccharides Chemical class 0.000 claims description 2
- 239000004337 magnesium citrate Substances 0.000 claims description 2
- 229960005336 magnesium citrate Drugs 0.000 claims description 2
- 235000002538 magnesium citrate Nutrition 0.000 claims description 2
- 239000001508 potassium citrate Substances 0.000 claims description 2
- 229960002635 potassium citrate Drugs 0.000 claims description 2
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 claims description 2
- 235000011082 potassium citrates Nutrition 0.000 claims description 2
- 230000002265 prevention Effects 0.000 claims description 2
- MUPFEKGTMRGPLJ-ZQSKZDJDSA-N raffinose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@@H]2[C@@H]([C@@H](O)[C@@H](O)[C@@H](CO)O2)O)O1 MUPFEKGTMRGPLJ-ZQSKZDJDSA-N 0.000 claims description 2
- 235000013337 tricalcium citrate Nutrition 0.000 claims description 2
- PLSARIKBYIPYPF-UHFFFAOYSA-H trimagnesium dicitrate Chemical compound [Mg+2].[Mg+2].[Mg+2].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O PLSARIKBYIPYPF-UHFFFAOYSA-H 0.000 claims description 2
- 239000002417 nutraceutical Substances 0.000 claims 1
- 235000021436 nutraceutical agent Nutrition 0.000 claims 1
- YPSNMKHPDJVGEX-UHFFFAOYSA-L potassium;sodium;3-carboxy-3-hydroxypentanedioate Chemical compound [Na+].[K+].OC(=O)CC(O)(C([O-])=O)CC([O-])=O YPSNMKHPDJVGEX-UHFFFAOYSA-L 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 20
- 239000008280 blood Substances 0.000 abstract description 17
- 210000004369 blood Anatomy 0.000 abstract description 17
- 239000000843 powder Substances 0.000 abstract description 6
- 239000002131 composite material Substances 0.000 abstract description 4
- 210000001503 joint Anatomy 0.000 description 9
- 230000029142 excretion Effects 0.000 description 7
- 244000005700 microbiome Species 0.000 description 7
- 230000035945 sensitivity Effects 0.000 description 7
- 230000001154 acute effect Effects 0.000 description 6
- 108010093894 Xanthine oxidase Proteins 0.000 description 5
- 102100033220 Xanthine oxidase Human genes 0.000 description 5
- 230000000968 intestinal effect Effects 0.000 description 5
- KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 4
- 230000001684 chronic effect Effects 0.000 description 4
- 230000006872 improvement Effects 0.000 description 4
- 238000000034 method Methods 0.000 description 4
- 238000009629 microbiological culture Methods 0.000 description 4
- 238000004393 prognosis Methods 0.000 description 4
- 206010018634 Gouty Arthritis Diseases 0.000 description 3
- 206010061218 Inflammation Diseases 0.000 description 3
- 230000003247 decreasing effect Effects 0.000 description 3
- 238000003745 diagnosis Methods 0.000 description 3
- 230000004054 inflammatory process Effects 0.000 description 3
- 230000009916 joint effect Effects 0.000 description 3
- 210000003734 kidney Anatomy 0.000 description 3
- 230000008569 process Effects 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000002829 reductive effect Effects 0.000 description 3
- 239000011734 sodium Substances 0.000 description 3
- 208000024891 symptom Diseases 0.000 description 3
- 210000001179 synovial fluid Anatomy 0.000 description 3
- IAKHMKGGTNLKSZ-INIZCTEOSA-N (S)-colchicine Chemical compound C1([C@@H](NC(C)=O)CC2)=CC(=O)C(OC)=CC=C1C1=C2C=C(OC)C(OC)=C1OC IAKHMKGGTNLKSZ-INIZCTEOSA-N 0.000 description 2
- 208000006820 Arthralgia Diseases 0.000 description 2
- 108010078791 Carrier Proteins Proteins 0.000 description 2
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 2
- 206010020649 Hyperkeratosis Diseases 0.000 description 2
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 2
- 206010023232 Joint swelling Diseases 0.000 description 2
- 206010042674 Swelling Diseases 0.000 description 2
- 108010092464 Urate Oxidase Proteins 0.000 description 2
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 description 2
- 210000003423 ankle Anatomy 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000009286 beneficial effect Effects 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 238000013170 computed tomography imaging Methods 0.000 description 2
- 210000002808 connective tissue Anatomy 0.000 description 2
- 230000008021 deposition Effects 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 206010012601 diabetes mellitus Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 210000001513 elbow Anatomy 0.000 description 2
- 238000000605 extraction Methods 0.000 description 2
- 210000002683 foot Anatomy 0.000 description 2
- 210000001035 gastrointestinal tract Anatomy 0.000 description 2
- 238000003384 imaging method Methods 0.000 description 2
- 210000003127 knee Anatomy 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000007937 lozenge Substances 0.000 description 2
- 208000030159 metabolic disease Diseases 0.000 description 2
- 239000002207 metabolite Substances 0.000 description 2
- 210000000878 metatarsophalangeal joint Anatomy 0.000 description 2
- MRWXACSTFXYYMV-FDDDBJFASA-N nebularine Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1C2=NC=NC=C2N=C1 MRWXACSTFXYYMV-FDDDBJFASA-N 0.000 description 2
- 239000002212 purine nucleoside Substances 0.000 description 2
- 229910052708 sodium Inorganic materials 0.000 description 2
- 239000000243 solution Substances 0.000 description 2
- 230000008961 swelling Effects 0.000 description 2
- 239000006188 syrup Substances 0.000 description 2
- 235000020357 syrup Nutrition 0.000 description 2
- 238000012360 testing method Methods 0.000 description 2
- 238000002604 ultrasonography Methods 0.000 description 2
- 229940005267 urate oxidase Drugs 0.000 description 2
- 210000002700 urine Anatomy 0.000 description 2
- 210000000707 wrist Anatomy 0.000 description 2
- 206010067484 Adverse reaction Diseases 0.000 description 1
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 description 1
- 208000036487 Arthropathies Diseases 0.000 description 1
- 102100022595 Broad substrate specificity ATP-binding cassette transporter ABCG2 Human genes 0.000 description 1
- 241001260012 Bursa Species 0.000 description 1
- 102000014914 Carrier Proteins Human genes 0.000 description 1
- 229920002261 Corn starch Polymers 0.000 description 1
- 229920000832 Cutin Polymers 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018641 Gouty tophus Diseases 0.000 description 1
- 101000821903 Homo sapiens Solute carrier family 22 member 12 Proteins 0.000 description 1
- 208000031226 Hyperlipidaemia Diseases 0.000 description 1
- 206010020772 Hypertension Diseases 0.000 description 1
- 208000012659 Joint disease Diseases 0.000 description 1
- 208000000913 Kidney Calculi Diseases 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 108010090306 Member 2 Subfamily G ATP Binding Cassette Transporter Proteins 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 206010029148 Nephrolithiasis Diseases 0.000 description 1
- 206010030113 Oedema Diseases 0.000 description 1
- 208000002193 Pain Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical group [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 102100021495 Solute carrier family 22 member 12 Human genes 0.000 description 1
- 241001052560 Thallis Species 0.000 description 1
- 208000020312 Thickened skin Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- 210000000142 acromioclavicular joint Anatomy 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000006838 adverse reaction Effects 0.000 description 1
- 229960000458 allantoin Drugs 0.000 description 1
- 230000000202 analgesic effect Effects 0.000 description 1
- 229940035676 analgesics Drugs 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 210000000709 aorta Anatomy 0.000 description 1
- 239000003833 bile salt Substances 0.000 description 1
- 229940093761 bile salts Drugs 0.000 description 1
- 230000008033 biological extinction Effects 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 210000000845 cartilage Anatomy 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229940112822 chewing gum Drugs 0.000 description 1
- 235000015218 chewing gum Nutrition 0.000 description 1
- 208000020832 chronic kidney disease Diseases 0.000 description 1
- 229960001338 colchicine Drugs 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 230000002860 competitive effect Effects 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 239000008120 corn starch Substances 0.000 description 1
- 229940099112 cornstarch Drugs 0.000 description 1
- 230000007812 deficiency Effects 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- OLSDWRNWUGHKSY-UHFFFAOYSA-J dicalcium;phosphonato phosphate;dihydrate Chemical compound O.O.[Ca+2].[Ca+2].[O-]P([O-])(=O)OP([O-])([O-])=O OLSDWRNWUGHKSY-UHFFFAOYSA-J 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000016097 disease of metabolism Diseases 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 229940088598 enzyme Drugs 0.000 description 1
- 210000000744 eyelid Anatomy 0.000 description 1
- 210000003811 finger Anatomy 0.000 description 1
- 210000001145 finger joint Anatomy 0.000 description 1
- 210000004904 fingernail bed Anatomy 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 210000004211 gastric acid Anatomy 0.000 description 1
- 239000003862 glucocorticoid Substances 0.000 description 1
- PCHJSUWPFVWCPO-UHFFFAOYSA-N gold Chemical compound [Au] PCHJSUWPFVWCPO-UHFFFAOYSA-N 0.000 description 1
- 210000003709 heart valve Anatomy 0.000 description 1
- 210000000474 heel Anatomy 0.000 description 1
- COSZWAUYIUYQBS-UHFFFAOYSA-B hexapotassium hexasodium 3-carboxy-3-hydroxypentanedioate 2-hydroxypropane-1,2,3-tricarboxylate hydrate Chemical compound O.[Na+].[Na+].[Na+].[Na+].[Na+].[Na+].[K+].[K+].[K+].[K+].[K+].[K+].OC(=O)CC(O)(C(O)=O)CC(O)=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O.[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O COSZWAUYIUYQBS-UHFFFAOYSA-B 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000002452 interceptive effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- 210000000281 joint capsule Anatomy 0.000 description 1
- 208000017169 kidney disease Diseases 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 230000002906 microbiologic effect Effects 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 238000000386 microscopy Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- 210000000282 nail Anatomy 0.000 description 1
- 210000002184 nasal cartilage Anatomy 0.000 description 1
- 201000008383 nephritis Diseases 0.000 description 1
- 230000008058 pain sensation Effects 0.000 description 1
- 206010033675 panniculitis Diseases 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 239000002213 purine nucleotide Substances 0.000 description 1
- 150000003212 purines Chemical class 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000009103 reabsorption Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 238000012216 screening Methods 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 210000001898 sternoclavicular joint Anatomy 0.000 description 1
- 210000004304 subcutaneous tissue Anatomy 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 208000010731 swelling symptom Diseases 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 210000001738 temporomandibular joint Anatomy 0.000 description 1
- 210000002435 tendon Anatomy 0.000 description 1
- 210000002105 tongue Anatomy 0.000 description 1
- 238000011269 treatment regimen Methods 0.000 description 1
- 230000001751 uricolytic effect Effects 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
- 210000001260 vocal cord Anatomy 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 239000003064 xanthine oxidase inhibitor Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/125—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives containing carbohydrate syrups; containing sugars; containing sugar alcohols; containing starch hydrolysates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/194—Carboxylic acids, e.g. valproic acid having two or more carboxyl groups, e.g. succinic, maleic or phthalic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/702—Oligosaccharides, i.e. having three to five saccharide radicals attached to each other by glycosidic linkages
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/733—Fructosans, e.g. inulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Molecular Biology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Rheumatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Physical Education & Sports Medicine (AREA)
- Pain & Pain Management (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
The invention provides a composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof, wherein the composition comprises a probiotic composition and prebiotics; wherein the probiotic composition is one or more of lactobacillus reuteri, lactobacillus fermentum, bacillus coagulans, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum, and the mass ratio of the probiotic composition to the prebiotics is (1-80): (1-80). According to the invention, the probiotic composition and the prebiotics are combined, the prepared composite bacteria powder can obviously reduce the blood uric acid of gout patients, and the crystal dissolving effect of the composite bacteria powder is verified through dual-energy CT for the first time.
Description
Technical Field
The invention relates to the technical field of prevention and treatment of hyperuricemia and gout, and in particular relates to a composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof.
Background
Gout (Gout) is crystal-related arthropathy caused by deposition of mono-natrium urate, is directly related to hyperuricemia caused by purine metabolic disorder and reduction of uric acid excretion, and belongs to the category of metabolic rheumatism. The clinical symptoms of gout are severe pain, edema, redness and inflammation at the joint area, the first attack usually involves a single joint, most commonly the first metatarsophalangeal joint, and the subsequent attack may involve multiple joints such as instep, ankle, heel, knee, wrist, fingers and elbow, with fever; the number of the patients with the first attack and the involvement of multiple joints is 3-14%; acute gout rarely affects shoulder, hip, spine, sacral, sternoclavicular, acromioclavicular or temporomandibular joints. The pain sensation slowly diminishes until it disappears, lasting for days or weeks. Uric acid crystals in patients with chronic gouty arthritis and tophus are preferentially deposited on cartilages of various joints such as wrists, ankles, knees, elbows, metatarsophalangeal joints, finger joints and the like, urate crystals are often deposited on bursa, earrings, tendon sheaths, subcutaneous tissues, renal interstitium and the like, and even a few patients deposit and aggregate the uric acid crystals into tophus on nasal cartilages, tongues, vocal cords, eyelids, aorta, heart valves and cardiac muscle, so that the health of the people is seriously harmed.
According to statistics, the hyperuricemia patients in China exceed 1.8 hundred million, and the total morbidity is about 13.3 percent; gout patients in China already exceed 8000 ten thousand, and the annual growth rate of gout patients is rapidly increased by 9.7% every year, and gout becomes the second largest metabolic disease second to diabetes in China. Gout patients, if left untreated or treated incorrectly, have about 12% of patients who develop tophi after 5 years, and about 70% of patients who develop tophi after 20 years. According to statistics, the disease cause of 90% of gout patients is that the excretion of the kidney is reduced, so that the kidney diseases such as acute nephritis, chronic renal insufficiency and kidney stones are caused; moreover, 50-70% of gout patients are obese, and the proportion of patients with gout complicated with hypertension, hyperlipidemia and diabetes is 47.2-77.7%, 67% and 12.2-26.9%, respectively.
In the prior art, gout diagnosis usually adopts clinical manifestation examination, laboratory examination and imaging examination; the necessary condition for the admission of the diagnosis process is 'at least 1 time of joint swelling, pain or tenderness', the 'sodium urate crystal is found in the joint or synovial fluid, or tophus appears in connective tissue' as the sufficient condition for the confirmation, if the sufficient condition is not met, the score is accumulated according to the clinical symptoms, physical signs, laboratory and imaging examination results. The detection method of urate crystals in joint or synovial fluid or tophus in connective tissue mainly comprises invasive synovial fluid extraction microscopy, non-invasive musculoskeletal B-ultrasound and dual-energy CT; among them, the "invasive synovial capsule fluid extraction microscopic examination urate crystals" is the current gold standard for gout diagnosis, but with the technical progress, the sensitivity and specificity of musculoskeletal B-ultrasonography and dual-energy CT are also very high. The sensitivity and specificity of the musculoskeletal B ultrasonic are respectively 100% and 76.2%, and the factors interfering with the specificity are mainly calcium pyrophosphate dihydrate deposits deposited at joints. For patients with a history of more than 2 years, the sensitivity and specificity of dual-energy CT are 92.86% and 88.24%, respectively, and the interference factor is mainly < 2mm MSU and is easy to miss. Lower density, non-tophus MSUs are easily missed, and artifacts are common on the nails and nail bed of the foot, thickened skin and calluses on the sole of the foot. The reason is that cutin, calluses and MSU have similar attenuation characteristics under X-ray.
In the prior art, there are three main uric acid lowering strategies for clinically treating hyperuricemia and gout, wherein firstly, uric acid generation is inhibited, and most of the medicines are xanthine oxidase inhibitors, such as allopurinol, febuxostat and the like; secondly, the excretion of uric acid is increased, and the drugs mostly act on uric acid transport proteins and the like, such as probenecid, benzbromarone and the like; and thirdly, novel uricolytic drugs, such as labyrinase and pegolose. In addition, analgesic and anti-inflammatory drugs for relieving acute gout attack, such as colchicine and glucocorticoid, etc., are also available. All the medicines are treatment strategies for relieving symptoms and root causes of uric acid, and once the medicines are stopped, the uric acid can quickly rise to the level before treatment, and the reason is that the gout is fundamentally caused by: the xanthine oxidase enriched in the liver abnormally expresses and has high activity; abnormal expression of uric acid transporters in the kidney and intestine; the disorder of the intestinal microorganisms causes the accumulation of xanthine oxidase and the deletion of allantoin enzyme in the intestinal microorganisms, and metabolites induce the chronic systemic inflammation of the organism to cause the increase of endogenous uric acid. However, the medicines cannot solve the basic causes of the gout, and only can simply inhibit the activity of xanthine oxidase, inhibit the reabsorption capability of URAT1, improve the secretion activity of ABCG2 and degrade blood uric acid; moreover, the uric acid crystals dissolved and deposited by the medicines and the tophus are harsh, and the blood uric acid needs to be continuously maintained to be lower than 360 mu mol/L; in addition, these drugs have great damage to liver and kidney, cannot be used for multiple purposes, and cannot be used for a long time, so that many patients abandon the treatment of the drugs due to intolerable side effects.
Disclosure of Invention
The invention aims to provide a composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof.
The invention adopts the following technical scheme:
a composition for reducing uric acid, dissolving uric acid crystal and tophus comprises probiotic composition and prebiotics.
Wherein the probiotic composition is one or more of lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum.
In detail, in the above composition, the strain in the probiotic composition is resistant to gastric acid and bile salts, and its metabolite can increase Na+-K+Pump and Ca-ATPase activity, increase urate solubility and inhibit crystal deposition, promoteThe crystals are dissolved, in addition, purine nucleotide in food can be specifically degraded into purine nucleoside and purine base with low solubility, and the purine nucleoside and the purine base are discharged out of the body along with thalli, so that exogenous uric acid is reduced; the bacterial strains in the probiotic composition are planted in a competitive manner with harmful microorganisms in the intestinal tract, so that the intestinal micro-ecology is improved, and the flora structure of xanthine oxidase enrichment and urate oxidase deficiency in bodies of gout patients is relieved. The prebiotics can assist the growth and reproduction of the bacterial strains of the probiotic composition in the intestinal tract, improve the intestinal microecology of gout patients, inhibit the growth and the multiplication of xanthine oxidase strains, promote the enrichment of the urate oxidase strains and promote the intestinal excretion of uric acid.
In the above technical scheme, in the composition capable of reducing uric acid, dissolving uric acid crystals and tophus, the adding amount weight ratio of the probiotic composition to the prebiotics is (1-80): (1-80), preferably (8-32): (40-80).
In detail, in the above technical scheme, when the ratio of the added amounts of the probiotic composition and the prebiotics is within the range, the optimal survival and colonization of the probiotic composition can be ensured, so that the functional efficiency of the strain is optimized; and can also avoid the occurrence of ' Hersche ' extinction reaction ' of gout patients.
In the above technical scheme, the total viable count of the probiotic composition is 1 x 106-6*1012 CFU/g。
Preferably, in the above technical solution, the number of single viable bacteria in lactobacillus reuteri, lactobacillus fermentum, bacillus coagulans, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum is 1.2 × 10 respectively9-2.1*1012CFU/g、1.1*109-2.0*1012CFU/g、1.3*108- 1.5*1011CFU/g、1.3*109-2.1*1012CFU/g、1.0*109-1.4*1012CFU/g and 5 x 109-1.2*1012CFU/g。
Specifically, in the technical scheme, the lactobacillus reuteri is one or more of lactobacillus reuteri KLR-1 with the preservation number of CGMCC No.18699, lactobacillus reuteri KLR-3 with the preservation number of CGMCC No.18700, lactobacillus reuteri KLR-4 with the preservation number of CCTCC No. M2020367 and lactobacillus reuteri KLR-13 with the preservation number of CGMCC No. 19329.
Specifically, in the technical scheme, the lactobacillus rhamnosus is lactobacillus rhamnosus KLrh-10 with the preservation number of CGMCC No. 19711.
Specifically, in the technical scheme, the lactobacillus casei is lactobacillus casei KLca-10 with the preservation number of CGMCC No. 19708.
Specifically, in the technical scheme, the lactobacillus plantarum is lactobacillus plantarum KLpl-3 with the preservation number of CCTCC No. M2020366.
Still further, in the above technical scheme, the composition further comprises citric acid, wherein the citric acid is one or more of citric acid, citric acid ester and citric acid salt.
Preferably, in the above technical scheme, the probiotic composition, the prebiotics and the citric acid are added in an amount of (1-80): (1-80): (1-50), more preferably (8-32): (40-80): (10-30).
In detail, in the technical scheme, when the addition amount of citric acid is in the range, the citrate can be ensured to alkalize urine, so that renal excretion of uric acid is promoted, and adverse reactions caused by long-term use can be avoided.
Specifically, in the above technical scheme, the citric acid is one or more of citric acid, potassium citrate, magnesium citrate, calcium citrate and sodium potassium hydrogen citrate.
In the above technical scheme, the prebiotics are one or more of inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, raffinose and stachyose.
The invention also provides application of the composition in preparing foods, medicines and health-care products for preventing and treating hyperuricemia and/or gout.
Specifically, the food, drug and health care product for preventing and treating hyperuricemia and/or gout is any one of solution, suspension, emulsion, powder, lozenge, pill, syrup, lozenge, tablet, chewing gum, thick syrup and capsule.
The invention also provides application of the composition and the uric acid discharging medicine in preparing foods, medicines and health-care products for dissolving urate crystallite and tophus.
Specifically, in the technical scheme, the uric acid reducing drug is one or more of allopurinol, febuxostat, benzbromarone and probenecid.
Further, in the above technical scheme, the adding amount mass ratio of the composition to the uric acid lowering drug is 100-1000: 1, preferably 300-: 1.
compared with the prior art, the invention has the beneficial effects that:
according to the invention, the probiotic composition and the prebiotics are combined, the prepared composite bacteria powder can obviously reduce the blood uric acid of gout patients, and the crystal dissolving effect of the composite bacteria powder is verified through dual-energy CT for the first time.
Drawings
FIG. 1 is a graph of dual-energy CT imaging results of a blank control group and pre-intervention and dry prognosis using compositions 1, 3, 4 and 6, respectively, in accordance with an embodiment of the present invention.
Detailed Description
The present invention is further described in detail below with reference to specific examples so that those skilled in the art can more clearly understand the present invention.
The following examples are given for the purpose of illustration only and are not intended to limit the scope of the invention.
All other embodiments obtained by a person skilled in the art based on the specific embodiments of the present invention without any inventive step are within the scope of the present invention.
In the examples of the present invention, all the raw material components are commercially available products well known to those skilled in the art unless otherwise specified.
In the examples of the present invention, unless otherwise specified, all technical means used are conventional means well known to those skilled in the art.
The separation and screening process of lactobacillus reuteri, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum used in the embodiment of the invention is described in the patent application No. 202010947184.8 entitled probiotic strain, composition and application thereof with purine-reducing precursor; the lactobacillus fermentum, the bacillus coagulans, the prebiotics and the citric acid used in the embodiment of the invention are all commercial products.
Lactobacillus reuteri KLR-1 is preserved in the general microorganism center of China Committee for culture Collection of microorganisms (CGMCC, address: No. 3 of the institute of microorganisms of the national academy of sciences, Japan, No. 100101) in 2019, 10.17.8.4.4.4.4.4.4.4.4.4.9.4.9.4.9.3.9.9.9.9.9.9.9.9.9.9.9.9.9.4.9.9.9.9.9.9.4.9.9.9.9.A preservation number is CGMCC No. 18699.
Lactobacillus reuteri KLR-3 is preserved in the general microorganism center of China Committee for culture Collection of microorganisms (CGMCC, address: No. 3 of the institute of microorganisms of the national academy of sciences, Japan, No. 100101) in 2019, 10.17.8.9.4.4.4.4.4.3.A preservation number is CGMCC No. 18700.
Lactobacillus reuteri KLR-4 is preserved in China center for type culture Collection (CCTCC, address: Wuhan, university of Wuhan, China; zip code: 430072) in 2020, 7 months and 28 days, and the preservation number is CCTCC No. M2020367.
Lactobacillus reuteri KLR-13 is preserved in China general microbiological culture Collection center (CGMCC, address: No. 3 of West Luo 1 of Beijing university facing Yang district, Japan institute of microbiology, postal code 100101) in 2020, 01, 10 days, and the preservation number is CGMCC No. 19329.
Lactobacillus rhamnosus KLrh-10 was deposited at the China general microbiological culture Collection center (CGMCC, address: Beijing Corp. Astrongyi-Chen Xilu No.1, institute of microbiology, China academy of sciences, postal code 100101) at 23.04.2020, and the number of the deposit is CGMCC No. 19711.
Lactobacillus casei (Lactobacillus casei) KLca-10 was deposited at China general microbiological culture Collection center (CGMCC, China academy of sciences microbiological research institute, postal code 100101) at 04.23.2020/04 in China general microbiological culture Collection center (CGMCC, address: Beijing, West Lu No.1, Taiyang district, China academy of sciences), with the collection number of CGMCC No. 19708.
Lactobacillus plantarum KLpl-3 is preserved in China center for type culture Collection (CCTCC for short, address: Wuhan, Wuhan university, China; zip code: 430072) in 7-month and 28-month 2020, with the preservation number of CCTCC No. M2020366.
EXAMPLE preparation of oral compositions for reducing uric acid, dissolving uric acid crystals
Respectively containing Lactobacillus reuteri (viable count of 1.2 x 10)9-2.1*1012CFU/g), Lactobacillus fermentum (viable count 1.1 x 10)9-2.0*1012CFU/g), Bacillus coagulans (viable count 1.3 x 10)8-1.5*1011CFU/g), Lactobacillus rhamnosus (viable count 1.3 x 10)9-2.1* 1012CFU/g), Lactobacillus casei (viable count 1.0 x 10)9-1.4*1012CFU/g) and Lactobacillus plantarum (viable count 5 x 10)9-1.2*1012CFU/g) probiotic freeze-dried powder, prebiotics (inulin, xylo-oligosaccharide, stachyose and the like) and citric acid are combined, and the proportion of active ingredients is shown in table 1.
TABLE 1 product formulation for oral compositions that solubilize uric acid crystals
Effect verification
1. Observation of blood uric acid reducing effect of oral composition for dissolving uric acid crystal and tophus
120 chronic gouty arthritis patients (gout history is 3-15 years, attack frequency is less than or equal to 20 times/year) are collected to be used as volunteers, the patients are randomly divided into 8 groups, each group comprises 15 patients, and the intervention modes are respectively as follows: no intervention, composition 1 intervention, composition 2 intervention, composition 3 intervention, composition 4 intervention, composition 5 intervention, composition 6 intervention, composition 7 intervention, with an intervention cycle of 90 days, in the same manner: by adding adjuvants (such as maltodextrin, corn starch and microcrystalline cellulose), the composition is 10g, and is taken 1-2 hr after breakfast and supper with warm water below 42 deg.C for 10 g/time. Measuring the level of serum uric acid before intervention and on days 15, 30, 45, 60, 75, and 90 after intervention; the volume of the joint urate crystal is measured by adopting dual-energy CT before intervention and after intervention for 90 days, and the dissolving effect of the sodium urate crystal before and after intervention is evaluated. Meanwhile, a volunteer self-reporting mode is adopted to collect red heat, swelling, acute attack and joint activity sensitivity of the joint, so that whether the joint activity is improved or not is evaluated, and the times of gout attack and the improvement effect of the joint activity in intervention are evaluated.
TABLE 2 data for blood uric acid expected (mean. + -. standard deviation)
Data (table 2) of blood uric acid detection during product intervention periods show that after the results of the compositions 1, 3, 4, 5, 6 and 7 are obtained, blood uric acid of patients with chronic gouty arthritis and patients with tophus are increased to different degrees, the duration is shortest about 15 days and longest about 45 days, then the blood uric acid begins to decrease and is finally lower than the uric acid level before intervention, bacteria are beneficial in the intervention mode of an experimental group with the condition, the reason for the phenomenon is presumed to be that the uric acid excretion capacity of the patients with gout is weaker than that of healthy people, and the probiotics promote the dissolution of urate crystals deposited at joints, so that the phenomenon that the blood uric acid is increased and then decreased in the early stage of intervention finally occurs. The prognosis for 7 different compositions was 5 (33.33%), 0 (0%), 10 (66.67%), 5 (33.33%), 6 (40.00%), 11 (73.33%), 1 (6.67%), respectively, for patients with blood uric acid levels below 420 μmol/L. Namely the intervention effect: composition 6, composition 3 > composition 1, composition 4, composition 5 > composition 2 > composition 7, and composition 3 was not significantly different from composition 6, and composition 1, composition 4, and composition 5 were not significantly different. At present, clinically, citrate still used in China alkalifies urine to further promote uric acid excretion, namely the composition 7 has a certain capacity of reducing uric acid in a short term, but has a limited effect of reducing uric acid in a long term.
2. Observation of gout attack times and joint movement by oral composition
The number of acute attacks of the joints within the collection of the dry expectations of the volunteers was collected and statistically analyzed. The results show that the number of self-reported gout flares by the test subjects during the product intervention (table 3) showed a reduction in the number of gout flares after the intervention, as compared to the control, with the best results being compositions 3 and 6, followed by compositions 1, 4 and 5, and followed by composition 2 and the worst effect of composition 7. Among them, the effects of the compositions 3 and 6 were not significantly different, and the effects of the compositions 1, 4 and 5 were not significantly different.
TABLE 3 number of acute gout attacks in volunteers
The joint red heat and swelling reported by the test volunteers were collected for statistics and the results (table 4) are shown.
The results of the number of volunteers with red-hot, swollen joints compared to the control group showed: the intervention groups of composition 1, composition 3, composition 4, composition 5 and composition 6 showed increased frequency in the first month, decreased in the second month and decreased significantly in the third month, and the intervention groups of different compositions had no significant difference; the differences among the control, composition 2 and composition 7 intervention groups were not significant.
Results of the number of volunteers with improved joint sensitivity compared to the control group showed: after 90 days of intervention, the joint sensitivity of volunteers in the group of composition 1, composition 3, composition 4, composition 5 and composition 6 was significantly improved, wherein the composition 3 and composition 6 were superior to the composition 4 and composition 5, and the effect of the composition 1 was weaker than that of the composition 4; the differences among the control, composition 2 and composition 7 intervention groups were not significant.
Overall, the results of evaluating the improvement in the joints of volunteers by joint red heat, swelling symptoms and joint sensitivity showed that composition 3, composition 6 > composition 4, composition 5 > composition 1 > composition 7.
TABLE 4 improvement of Joint movement
3. Observation of Effect of orally administered composition in dissolving urate Crystal
FIG. 1 shows the dual-energy CT imaging results of the blank control group and the pre-intervention and post-intervention and dry prognosis using compositions 1, 3, 4 and 6, respectively, and Table 5 shows the results of the volume changes of urate crystals deposited before and after intervention, from which it can be seen that there is a reduction in urate crystals before and after intervention, especially after the dry prognosis of compositions 3 and 6, and the urate crystals deposited at the joints are significantly reduced compared to the control group; the crystal dissolving effect of the composition 3 and the composition 6 has no significant difference. In the colors marked on the dual-energy CT film in FIG. 1, purple represents deposited calcium salt and green represents deposited urate crystals; the results further confirm that the reason for elevated blood uric acid early in the intervention is the dissolution of urate crystals deposited at the joints.
TABLE 5 Change in volume of urate crystals deposited before and after intervention
4. Combination of uric acid crystal and tophus dissolving composition and uric acid reducing drug
The process of dissolving uric acid crystals and tophus can enable uric acid in blood to rise for a period of time, so that acute gout inflammation can be caused, and in order to relieve the rise of blood uric acid caused by dissolution of uric acid crystals or tophus, the mode of using the composition 6 in combination with a small-dose uric acid reducing medicine is considered, so that the effect of inhibiting the rise of blood uric acid is inhibited.
50 hyperuricemia patients with tophus were recruited as volunteers, divided into 5 groups, and the change of blood uric acid during intervention was observed by using composition 6 and uric acid lowering drugs (febuxostat 20 mg/day and benzbromarone 25 mg/day, respectively) alone or in combination.
TABLE 6 uric acid lowering Effect of the combination with an acid-excreting drug
As shown in the analysis table 6, small doses of febuxostat and benzbromarone can inhibit the increase of blood uric acid caused by the crystal dissolution of the composition 6.
Finally, the method of the present invention is only a preferred embodiment and is not intended to limit the scope of the present invention. Any modification, equivalent replacement, or improvement made within the spirit and principle of the present invention should be included in the protection scope of the present invention.
Claims (10)
1. A composition for reducing uric acid, dissolving uric acid crystal and tophus is characterized in that,
comprising a probiotic composition and a prebiotic;
wherein the probiotic composition is one or more of lactobacillus reuteri, lactobacillus fermentum, bacillus coagulans, lactobacillus rhamnosus, lactobacillus casei and lactobacillus plantarum.
2. The uric acid lowering, uric acid crystal dissolving and tophus composition according to claim 1,
the adding amount weight ratio of the probiotic composition to the prebiotics is (1-80): (1-80), preferably (8-32): (40-80).
3. The uric acid lowering, uric acid crystal dissolving and tophus composition according to claim 1,
the total viable count of the probiotic composition is 1 x 106-6*1012CFU/g；
Preferably, the number of single viable bacteria in the lactobacillus reuteri, the lactobacillus fermentum, the bacillus coagulans, the lactobacillus rhamnosus, the lactobacillus casei and the lactobacillus plantarum is 1.2 x 10 respectively9-2.1*1012CFU/g、1.1*109-2.0*1012CFU/g、1.3*108-1.5*1011CFU/g、1.3*109-2.1*1012CFU/g、1.0*109-1.4*1012CFU/g and 5 x 109-1.2*1012CFU/g。
4. The uric acid lowering, uric acid crystal dissolving and tophus composition according to any one of claims 1 to 3,
the lactobacillus reuteri is one or more of lactobacillus reuteri KLR-1 with the preservation number of CGMCC No.18699, lactobacillus reuteri KLR-3 with the preservation number of CGMCC No.18700, lactobacillus reuteri KLR-4 with the preservation number of CCTCC No. M2020367 and lactobacillus reuteri KLR-13 with the preservation number of CGMCC No. 19329;
and/or the lactobacillus rhamnosus is lactobacillus rhamnosus KLrh-10 with the preservation number of CGMCC No. 19711;
and/or the lactobacillus casei is lactobacillus casei KLca-10 with the preservation number of CGMCC No. 19708;
and/or the lactobacillus plantarum is lactobacillus plantarum KLpl-3 with the preservation number of CCTCC No. M2020366.
5. The uric acid lowering, uric acid crystal dissolving and tophus composition according to any one of claims 1 to 4,
the citric acid is one or more of citric acid, citric acid ester and citric acid salt;
preferably, the probiotic composition, the prebiotics and the citric acid are added in a weight ratio of (1-80): (1-80): (1-50), more preferably (8-32): (40-80): (10-30);
further preferably, the citric acid is one or more of citric acid, potassium citrate, magnesium citrate, calcium citrate and sodium potassium citrate.
6. The uric acid lowering, uric acid crystal dissolving and tophus composition according to claim 1,
the prebiotics are one or more of inulin, fructo-oligosaccharide, galacto-oligosaccharide, xylo-oligosaccharide, raffinose and stachyose.
7. Use of the composition according to any one of claims 1 to 6 for the preparation of food, pharmaceutical and health care products for the prevention and treatment of hyperuricemia and/or gout.
8. Use of the composition of any one of claims 1-6 in combination with a uric acid lowering drug for the preparation of foods, pharmaceuticals and nutraceuticals for the dissolution of crystalline urate and tophus.
9. The use according to claim 8,
the uric acid reducing medicine is one or more of allopurinol, febuxostat, benzbromarone and probenecid.
10. Use according to claim 8 or 9,
the adding amount mass ratio of the composition to the uric acid discharging medicine is 100-1000: 1, preferably 300-: 1.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110272571.0A CN113181365B (en) | 2021-03-12 | 2021-03-12 | Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN202110272571.0A CN113181365B (en) | 2021-03-12 | 2021-03-12 | Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN113181365A true CN113181365A (en) | 2021-07-30 |
| CN113181365B CN113181365B (en) | 2022-08-09 |
Family
ID=76973273
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN202110272571.0A Active CN113181365B (en) | 2021-03-12 | 2021-03-12 | Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN113181365B (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999805A (en) * | 2021-12-06 | 2022-02-01 | 四川高福记生物科技有限公司 | Lactobacillus fermentum for preventing and treating hyperuricemia, and composition and application thereof |
| CN114432346A (en) * | 2022-03-24 | 2022-05-06 | 金华银河生物科技有限公司 | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof |
| CN114651983A (en) * | 2022-02-25 | 2022-06-24 | 天津科技大学 | Bacillus coagulans derived from shrimp paste and having uric acid reducing and antioxidant capabilities, method and application |
| CN115553424A (en) * | 2022-09-28 | 2023-01-03 | 广西弘山堂生物科技有限公司 | Preparation method of nutritional food for gout patients |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854495A (en) * | 2017-08-04 | 2018-03-30 | 青岛东海药业有限公司 | Bacillus coagulans is preparing the application in reducing blood urine acid supplement |
| CN108486007A (en) * | 2018-03-22 | 2018-09-04 | 嘉兴益诺康生物科技有限公司 | A kind of lactobacterium casei strains, probiotic composition and its application for reducing blood uric acid |
| CN110184209A (en) * | 2019-04-24 | 2019-08-30 | 杭州娃哈哈科技有限公司 | One plant of Lactobacillus rhamnosus that can reduce blood uric acid |
| CN111195266A (en) * | 2019-12-20 | 2020-05-26 | 江苏微康生物科技有限公司 | Probiotic composition with effect of relieving hyperuricemia and application thereof |
| CN112056399A (en) * | 2020-06-28 | 2020-12-11 | 武汉康复得生物科技股份有限公司 | Probiotic composition for enhancing immunity and application thereof |
| CN112263669A (en) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | Oligopeptide traditional Chinese medicine probiotic compound for relieving hyperuricemia |
-
2021
- 2021-03-12 CN CN202110272571.0A patent/CN113181365B/en active Active
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107854495A (en) * | 2017-08-04 | 2018-03-30 | 青岛东海药业有限公司 | Bacillus coagulans is preparing the application in reducing blood urine acid supplement |
| CN108486007A (en) * | 2018-03-22 | 2018-09-04 | 嘉兴益诺康生物科技有限公司 | A kind of lactobacterium casei strains, probiotic composition and its application for reducing blood uric acid |
| CN110184209A (en) * | 2019-04-24 | 2019-08-30 | 杭州娃哈哈科技有限公司 | One plant of Lactobacillus rhamnosus that can reduce blood uric acid |
| CN111195266A (en) * | 2019-12-20 | 2020-05-26 | 江苏微康生物科技有限公司 | Probiotic composition with effect of relieving hyperuricemia and application thereof |
| CN112056399A (en) * | 2020-06-28 | 2020-12-11 | 武汉康复得生物科技股份有限公司 | Probiotic composition for enhancing immunity and application thereof |
| CN112263669A (en) * | 2020-09-21 | 2021-01-26 | 康美华大基因技术有限公司 | Oligopeptide traditional Chinese medicine probiotic compound for relieving hyperuricemia |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN113999805A (en) * | 2021-12-06 | 2022-02-01 | 四川高福记生物科技有限公司 | Lactobacillus fermentum for preventing and treating hyperuricemia, and composition and application thereof |
| CN113999805B (en) * | 2021-12-06 | 2022-05-17 | 四川高福记生物科技有限公司 | Lactobacillus fermentum for preventing and treating hyperuricemia, and composition and application thereof |
| CN114651983A (en) * | 2022-02-25 | 2022-06-24 | 天津科技大学 | Bacillus coagulans derived from shrimp paste and having uric acid reducing and antioxidant capabilities, method and application |
| CN114651983B (en) * | 2022-02-25 | 2023-08-15 | 天津科技大学 | Bacillus coagulans with uric acid reducing and antioxidant capabilities and derived from shrimp paste, method and application |
| CN114432346A (en) * | 2022-03-24 | 2022-05-06 | 金华银河生物科技有限公司 | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof |
| CN115553424A (en) * | 2022-09-28 | 2023-01-03 | 广西弘山堂生物科技有限公司 | Preparation method of nutritional food for gout patients |
Also Published As
| Publication number | Publication date |
|---|---|
| CN113181365B (en) | 2022-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN113181365B (en) | Composition capable of reducing uric acid, dissolving uric acid crystals and tophus and application thereof | |
| US9308228B2 (en) | Supplemention of maternal diet | |
| CN110150669B (en) | Probiotic composition suitable for diabetic patients and application thereof | |
| JP2018532779A (en) | Felicaribacterium prausnitzi and desulfobibriopigel for use in the treatment or prevention of diabetes and bowel disease | |
| JP2012111771A (en) | Dietary fiber formulation, and method of administration | |
| CN104740138A (en) | Composition containing aloe, probiotics and prebiotics and application of composition | |
| US20100278795A1 (en) | Lactic acid bacterium-containing preparation | |
| WO2012016549A1 (en) | Use of salvia miltiorrhiza composition in preparing drugs for secondary prevention of coronary heart disease | |
| CN110623182A (en) | Probiotic plant solid beverage for treating hyperuricemia and gout | |
| CN113308421B (en) | Lactobacillus plantarum BUFX and application thereof in metabolic syndrome | |
| CN115305228A (en) | Probiotic composition for improving colorectal cancer symptoms and preparation method and application thereof | |
| WO2023124620A1 (en) | Use of c. minuta in preparation of medication for treating and/or preventing hyperuricemia-related diseases | |
| CN114432346A (en) | Composite probiotic composition for treating hyperuricemia and gout and preparation method and application thereof | |
| CN112770749A (en) | Application of combination of bifidobacterium and berberine in treating pre-diabetes and type 2 diabetes | |
| EP4185309A1 (en) | Microbial therapy | |
| CN113750113A (en) | Composition of probiotics and prebiotics and application thereof | |
| JP6650728B2 (en) | Formulations for diet | |
| CN115838675A (en) | Lactobacillus rhamnosus and composition and application thereof | |
| CN114272270A (en) | Application of lactobacillus gasseri LG08 in preparation of products for preventing and treating gout related diseases | |
| CN103037901B (en) | Suppress CD36 with obesity controlling and insulin sensitivity | |
| CN111281882B (en) | Compound preparation for promoting intestinal alkaline phosphatase expression and enhancing activity as well as preparation method, application method and application thereof | |
| CN110448569B (en) | Composition with antidiarrheal effect, preparation method and application thereof | |
| GB2617183A (en) | Alcohol degrading compositions and uses thereof | |
| US20240024385A1 (en) | Probiotic strain for reducing serum uric acid, composition and use thereof | |
| CN113768907A (en) | Application of heptadecyl resorcinol in preparation of product for improving muscle movement dysfunction |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PB01 | Publication | ||
| PB01 | Publication | ||
| SE01 | Entry into force of request for substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| TA01 | Transfer of patent application right | ||
| TA01 | Transfer of patent application right |
Effective date of registration: 20220615 Address after: 315000 Room 606, building 1, No. 24, Lane 216, ShanJia Road, No. 2622, Zhongshan East Road, Qiuai Town, Yinzhou District, Ningbo City, Zhejiang Province Applicant after: Ningbo beiyijia Biotechnology Co.,Ltd. Address before: 3 / F (1) factory building, phase 3.1, Wuhan Optics Valley International Biomedical accelerator, 388 Gaoxin 2nd Road, Donghu New Technology Development Zone, Wuhan City, Hubei Province, 430000 Applicant before: WUHAN KANGFUDE BIOTECHNOLOGY Co.,Ltd. |
|
| GR01 | Patent grant | ||
| GR01 | Patent grant |